Boston Cell Standards Inc.
Sharon, MA
- UEI
- HA17F32KXEV8
- CAGE
- 48QH5
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $1,995,119 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| FY24 sbir phase II RD contract - topic 442 boston cell standards, INC. | National Cancer Institute (NIH) | $1,995,119 | |
| Topic 442: quantitative traceable reference materials as mddts for tissue biomarkers | National Cancer Institute (NIH) | $385,889 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Boston Cell Standards Inc. is a for-profit corporate entity registered in SAM.gov since 2005, specializing in manufacturing medical devices, diagnostics, and related services. Located in Sharon, Massachusetts, the company focuses on developing advanced medical technologies, particularly in the field of cancer research and diagnostic standardization. Its primary expertise lies in creating quantitative traceable reference materials and improving laboratory testing standards for clinical immunohistochemistry (IHC).
Through federal contract awards, Boston Cell Standards Inc. has primarily worked with the National Cancer Institute (NCI) on Small Business Innovation Research (SBIR) contracts. The company was awarded two consecutive SBIR phase contracts totaling $2,381,008 to develop quantitative traceable reference materials for tissue biomarkers in cancer detection. These firm-fixed-price contracts were specifically set aside for small businesses and focused on creating medical device development tools to support cancer research. The Phase I contract, valued at $385,889, was awarded in September 2022 with completion in October 2023, while the Phase II contract, valued at $1,995,119, was awarded in September 2024 with an ultimate completion date of September 2026.
In terms of federal grant awards, Boston Cell Standards Inc. has received a significant grant from the National Cancer Institute to establish the National Immunohistochemistry Standardization Program. The grant, identified as R44CA268484 and valued at $5.1 million, aims to address the lack of reference standards in clinical immunohistochemistry laboratories. The project seeks to reduce analytic error rates, which currently range from 10-30% in IHC testing. The grant was awarded on September 21, 2021, with an expected completion date of August 31, 2024. Additionally, the company has been involved in a sub-grant related to the Central Hub for Kidney Precision Medicine, awarded on February 18, 2022, further demonstrating its involvement in medical research and standardization efforts.
Quick answers
Is Boston Cell Standards Inc. registered in SAM.gov?
Yes. Boston Cell Standards Inc.'s SAM.gov registration is active through April 5, 2027.
What is Boston Cell Standards Inc.'s CAGE code?
Boston Cell Standards Inc.'s CAGE code is 48QH5, and its Unique Entity ID (UEI) is HA17F32KXEV8.
How much has Boston Cell Standards Inc. received in federal contracts?
Federal contracts obligated $1,995,119 to Boston Cell Standards Inc. in fiscal years 2023 through 2027.
What is Boston Cell Standards Inc.'s most recent federal award?
Boston Cell Standards Inc.'s most recent federal contract award is FY24 sbir phase II RD contract - topic 442 boston cell standards, INC (75N91024C00087), from National Cancer Institute (NIH), on September 8, 2024.
On GovTribe
See Boston Cell Standards Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors